Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LEGN | 6-K | bullish | 7/10 | Legend Biotech announced first clinical proof-of-concept data for LB2501, its in vivo CD19/CD20 dual-targeting CAR-T the | Jun 15, 2026 |
| AAPG | 6-K | bullish | 6/10 | Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two core assets olveremb | Jun 15, 2026 |
| NVO | 6-K | neutral | 3/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Jun 15, 2026 |
| LXEO | 8-K | bullish | 6/10 | Lexeo Therapeutics finalized the SUNRISE-FA 2 pivotal trial protocol for LX2006 in Friedreich ataxia cardiomyopathy, wit | Jun 15, 2026 |
| LFCR | PRESS-RELEASE | bullish | 6/10 | Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for | Jun 15, 2026 |
| ELTP | 8-K | bullish | 5/10 | Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant ge | Jun 15, 2026 |
| AXSM | PRESS-RELEASE | neutral | 3/10 | Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes | Jun 15, 2026 |
| TNXP | CLUSTER | neutral | 3/10 | Three insiders including CEO Seth Lederman made small open-market purchases totaling $132K, representing ~0.07% of TNXP' | Jun 15, 2026 |
| XRTX | 6-K | neutral | 4/10 | XORTX Therapeutics filed a 6-K announcing the appointment of Mika Grasso as Co-CEO and providing a corporate update on i | Jun 15, 2026 |
| TLSA | 6-K | bullish | 4/10 | Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 15,000 common shares at $1.11 p | Jun 15, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone as the first | Jun 15, 2026 |
| PHVS | PRESS-RELEASE | bullish | 7/10 | Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset | Jun 15, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai reported Q1 2026 revenue of $489K (down 16.5% YoY) and an operating loss of $2.5M (widened from $1.6M). Net incom | Jun 15, 2026 |
| CNTX | PRESS-RELEASE | bullish | 7/10 | Context Therapeutics reported positive interim Phase 1 data for its CLDN6 x CD3 TCE bispecific antibody, CTIM-76, showin | Jun 15, 2026 |
| FLNA | 8-K | neutral | 3/10 | Filana Therapeutics held its 2026 Annual Meeting on June 11, 2026, where shareholders approved Amendment No. 2 to the 20 | Jun 15, 2026 |
| SVA | 6-K | bearish | 6/10 | Sinovac regained Nasdaq listing compliance following the long-delayed filing of its FY2025 20-F on June 5, 2026, which c | Jun 15, 2026 |
| RDY | 6-K | bullish | 6/10 | Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine ki | Jun 15, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed two 6-K reports on June 15, 2026, each containing an exhibit: one notification of cessation | Jun 15, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypopara | Jun 15, 2026 |
| EOLS | EFFECT | neutral | 3/10 | Evolus's S-3 shelf registration (File No. 333-296556) went effective on June 12, 2026, enabling the company to conduct o | Jun 15, 2026 |
| BLTE | 6-K | bullish | 6/10 | Belite Bio completed rolling submission of its New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy fo | Jun 15, 2026 |
| SNSE | EFFECT | bearish | 6/10 | The SEC declared effective Sensei Biotherapeutics' S-3 shelf registration on June 12, 2026, registering up to 24,868,028 | Jun 15, 2026 |
| FENC | PRESS-RELEASE | neutral | 2/10 | Fennec Pharmaceuticals granted 10,000 incentive stock options to a new non-executive employee at $9.00 per share under i | Jun 15, 2026 |
| AAPG | PRESS-RELEASE | mixed | 6/10 | Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation | Jun 14, 2026 |
| ZYME | PRESS-RELEASE | bullish | 6/10 | Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congres | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12 | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented two-year open-label extension data at ENDO 2026 showing that once-daily oral PALSONIFY (paltusotine) | Jun 14, 2026 |
| MRVI | INST-CLUSTER | mixed | 4/10 | During Q1 2026, six institutional investors increased their MRVI positions (net +$2.3M) while three trimmed (net -$256K) | Jun 14, 2026 |
| CLDX | PRESS-RELEASE | bearish | 6/10 | Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long | Jun 14, 2026 |
| UPB | PRESS-RELEASE | bullish | 7/10 | Upstream Bio presented positive responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP at EAACI 2026, | Jun 14, 2026 |